Vitamin D supplementation of daily and cardiac function in patients with advanced heart failure: The EVITA trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Who Took Part

The study group was 400 patients.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Of 400 patients enrolled, 199 were assigned to vitamin D and 201 to placebo.

The researchers assessed time × treatment interaction effects using linear mixed models and analyzed in subgroups vitamin D effects at 12 and 36 months post-randomization using analysis of covariance with adjustments for baseline values.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

The subject headings attached to it are Dietary Supplements, Heart Failure, Ventricular Function, Left and Vitamin D.

Author keywords: Echocardiography, Left ventricular ejection fraction and Randomized controlled trial.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 400 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (International journal of cardiology), a journal based in Netherlands.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.